On November 11, 2026, VectorY Therapeutics announced €74.5 million ($83.5 million) in new financing to advance its clinical and preclinical pipeline of vectorized antibody therapies for neurodegenerative diseases. The round includes new investors Angelini Ventures, Invest-NL and the European Investment Bank, alongside existing investors.

The funding will primarily support VTx-002, the company’s lead program for amyotrophic lateral sclerosis (ALS), through key clinical milestones, including the final readout of the global PIONEER-ALS Phase 1/2 study. VTx-002 uses an AAV vector to deliver genetic instructions for sustained antibody expression in the central nervous system, targeting pathological TDP-43 aggregates. The company’s broader pipeline includes VTx-003 for Huntington’s disease (mutant HTT), VTx-004 for frontotemporal dementia (TDP-43) and VTx-005 for Alzheimer’s disease (phosphorylated tau).

Notably, VectorY leverages the baculovirus/insect cell expression system for AAV manufacturing. Its optimized platform has demonstrated AAV manufacturing scalability of up to 2,000 L. As more AAV developers explore insect cell-based production, robust process development and scalable manufacturing capabilities will remain essential.

As part of the broader gene therapy ecosystem, Genevoyager provides end-to-end CRO/CDMO services, from drug discovery to large-scale manufacturing, leveraging both #HEK293 and our proprietary Bac/Sf9 AAV production platforms to produce high-quality AAV vectors with minimal impurities and no detectable rcAAV. With 30+ drug development projects and multiple IIT/IND submissions supported, Genevoyager has helped advance AAV-based gene therapies and recombinant protein vaccines into clinical development, including programs targeting Parkinson’s disease, refractory epilepsy, hepatitis B, and cancer, with selected programs receiving FDA IND clearance and entering Phase I trials. Backed by extensive experience, we are committed to delivering safe, high-quality solutions to academic, pharmaceutical, and biotech partners worldwide.

Source:

https://www.vectorytx.com/news/vectory-expands-pioneer-als-phase-12-clinical-trial-size-4jeae

https://www.vectorytx.com/vectorized-antibody-platform

Image source:

https://static1.squarespace.com/static/6393094bc2c21800678e46ed/t/69ba97b85140e9319dd0c10a/1773836218989/17MAR2026_ADPD2026+Oral+Presentation_Madhurima+Chatterjee_v3.pdf

Note: